ArticleJournal of surgical oncology2025
Fragmentation of Multimodal Rectal Cancer Care: A Population-Level Retrospective Cohort Study.
Article in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLocally advanced rectal cancer is often treated with multimodal therapy. Patients may receive care at a single institution or across multiple institutions. We designed this population-level retrospective cohort to determine the association between fragmented care and timeliness of treatment and long-term oncologic outcomes.
methodsPatients with stage II/III rectal cancer who received at least two treatment modalities between 2010 and 2019 in Ontario, Canada were included. Fragmented care was defined as receiving at least one treatment modality at two or more institutions, while nonfragmented care was defined as receiving all treatments at a single institution. The primary outcome was timeliness of treatment as defined by Cancer Care Ontario Recommendations. Secondary outcomes included overall survival (OS).
resultsOverall, 3381 patients received fragmented care and 2026 patients received nonfragmented care. Patients receiving nonfragmented care were more likely to undergo timely initiation of treatment (OR: 1.72, 95% CI: 1.50-1.97, p < 0.0001). This was driven by timely initiation of chemotherapy (OR: 1.32, 95% CI: 1.16-1.49, p < 0.0001). There was little to no difference in OS (HR: 1.11, 95% CI: 0.95-1.30, p = 0.19).
conclusionPatients with stage II/III rectal cancer receiving multimodal therapy may experience less timely initiation of treatment if their cancer care is fragmented. This did not translate into differences in long-term oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.